Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent

Abstract
A monoclonal anti-A antibody was evaluated and found suitable for use as a potent routine [human] ABO blood grouping reagent, without the use of additives. The IgM anti-A (MH2/6D4) is secreted into the tissue culture supernatant by a permanent line of cloned cells derived by fusion of anti-A producing spleen cells and a mouse myeloma cell line. This is a cost-effective reagent which should reduce production costs by over 50%. This reagent has the advantages inherent in monoclonal antibodies, among them the availability of unlimited quantities of unvarying antibody of known properties.